Request Discount

T cell Immunotherapy Market (Mechanism of Action - Active Immunotherapy, and Passive Immunotherapy; Type of Therapy - CAR-T, TCR, and TIL; Product Class - Monoclonal Antibodies, Oncolytic Virus Therapy, Bispecific Antibodies, and Cytokines): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

  • Published : April, 2021

  • Rep Id : HC0099

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on T cell immunotherapy market provides in-depth analysis of segments and sub-segments in the global as well as regional T cell immunotherapy market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional T cell immunotherapy market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global T cell immunotherapy market. According to the report, the global T cell immunotherapy market is projected to grow at a CAGR of 15.70% over the forecast period of 2020-2026.


T cell immunotherapy market

 

Market Insight

According to the WHO, Cancer is the second leading cause of death globally and is likely to account for 9.6 million death in 2018. T-Cell immunotherapy is the type of therapy in that cancer is treated by boosting the immune system in both children as well as adults. T-Cell is the white blood cells in the immune system that fight infection. In T-cell immunotherapy, the T-Cells are reprogrammed so they try to find and destroy the cancer cells present in the body. Each changed or reprogramed T-Cell injected into the body can multiply into thousands of new ones and stay in the body to keep killing cancer cells. Therefore, this therapy is also called a “living drug” in cancer treatment.

 

The growing occurrence of cancer in both children as well as in adults creates a huge demand for effective treatments. The rising incidence of cancer across the globe is a key factor driving the growth of the T-cell immunotherapy market. Reliable and effective treatments offered by the T-Cell with the minimum side effects as compared to the other traditional therapies are contributing to the growth of the T-cell immunotherapy market. In addition, on-going development to improve the existing therapies and rising innovations to provide more effective therapy options are anticipated to boost the growth of the T-cell immunotherapy market. However, the neurological problems associated with T-Cell immunotherapy is expected to be the restraining factor in the T-Cell immunotherapy market. Moreover, various health organizations and government agencies are taking the initiative to find effective therapy to treat cancer. The rapidly increasing research and development activities and technological advancement in cancer treatment are projected to create several opportunities for the T-Cell immunotherapy market in upcoming years. Furthermore, the food and drug administration (FDA) has approved CAR T-cell therapy, axicabtagene ciloleucel (Yescarta), for the treatment of diffuse large B-cell lymphoma (DLBCL) and CAR T-cell therapy tisagenlecleucel (Kymriah) to treat cancer in the children and adults.

 

Geographically, North America held the maximum market share in the T-Cell Immunotherapy market owing to the rising occurrence of cancer. The developed healthcare infrastructure of North America contributes to the growth of the T-cell Immunotherapy market. In addition, Asia-Pacific is the fastest-growing region in T-Cell Immunotherapy. The developing healthcare infrastructure, growing geriatric population, and rising occurrence of cancer are the primary factors driving the growth of the T-Cell Immunotherapy market in the Asia-Pacific region.

 

Segment Covered

The report on global T cell immunotherapy market covers segments such as mechanism of action, type of therapy, and product class. On the basis of mechanism of action, the sub-markets include active immunotherapy, and passive immunotherapy. On the basis of type of therapy, the sub-markets include CAR-T, TCR, and TIL. On the basis of product class, the sub-markets include monoclonal antibodies, oncolytic virus therapy, bispecific antibodies, and cytokines.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Adaptimmune Therapeutics, Bluebird Bio, Innovative Cellular Therapeutics, Novartis, Sinobioway Cell Therapy, Cellectis, CARsgen Therapeutics, Autolus ltd, Celgene, and Others.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of T cell immunotherapy market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount